Stem Cell Stocks through the Roof

[The Boys]

http://news.aol.com/main/obama-presidency/article/obama-stem-cell/344184

 

[The Boys]

Obama to Lift Stem Cell Restrictions

 

[vinnie]

Good morning The Boys :00hour

 

[The Boys]

Good morning The Boys :00hour

LOL

gern +40% after market

astm +82% after market

stem +67% after market

 

[dogface]

Stem cell stocks are going to be running with the obama announcement, here is a complete list!! Market Cap: $7.08M
$1-$10
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA)
Market Cap: $112.55M
ARIAD Pharmaceuticals, Inc. discovers and develops medicines to treat cancers by regulating cell signaling with small molecules.
Stock price: $1.45
http://www.ariad.com

BioHeart, Inc. (NASDAQ:BHRT)
Market Cap: $23.26M
BioHeart, Inc. develops and commercializes autologous (donor and recipient are the same) cell therapies for the treatment of chronic and acute heart damage.
Stock price: $1.11
http://www.bioheartinc.com/

Boston Scientific Corporation (NYSE:BSX)
Market Cap: $12.83B
Boston Scientific Corporation develops, manufactures and markets medical devices that are used in a broad range of interventional medical specialties including interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, oncology, endoscope, urology, gynecology and neuromodulation.
Stock price: $7.28
http://www.bostonscientific.com

Cambrex Corporation (NYSE:CBM)
Market Cap: $114.03M
Cambrex Corporation is a life sciences company that develops and manufactures pharmaceutical ingredients derived from organic chemistry for pharmaceutical and generic drug companies.
Stock price: $2.95
http://www.cambrex.com/

Cleveland BioLabs, Inc. (NASDAQ:CBLI)
Market Cap: $41.23M
Cleveland BioLabs, Inc. develops and commercializes products for cancer treatment and protection of normal tissues from radiation and toxins.
Stock price: $2.70
http://www.cbiolabs.com

Cerus Corporation (NASDAQ:CERS)
Market Cap: $35.75M
Cerus Corporation commercializes the INTERCEPT system designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company markets the INTERCEPT system for both platelets and plasma in Europe and the Middle East. Cerus is also pursuing regulatory approvals in the United States and other countries.
Stock price: $1.24
http://www.cerus.com/

Cytori Therapeutics, Inc. (NASDAQ:CYTX)
Market Cap: $89.08M
Cytori Therapeutics, Inc. develops, manufactures, and sells medical technologies to enable the practice of regenerative medicine. The company’s commercial activities are focused on reconstructive surgery in Europe and Asia-Pacific, and stem and regenerative cell banking in Japan.
Stock price: $2.44
http://www.cytoritx.com/

Neuralstem, Inc. (AMEX:CUR)
Market Cap: $59.48M
Neuralstem, Inc. develops and commercializes human neural stem cell technology in the field of regenerative medicine.
Stock price: $1.66
http://www.neuralstem.com/

Dendreon Corporation (NASDAQNDN)
Market Cap: $476.56M
Dendreon Corporation discovers, develops and commercializes therapeutics that harness the immune system to fight cancer.
Stock price: $4.95
http://www.dendreon.com/

Geron Corporation (NASDAQ:GERN)
Market Cap: $307.17M
Geron Corporation develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The Company is advancing telomerase targeted therapies, including an anti-cancer drug and a cancer vaccine, through multiple clinical trials. Geron also develops human embryonic stem cell-based therapeutics.
Stock price: $3.66
http://www.geron.com/

Incyte Corporation (NASDAQ:INCY)
Market Cap: $411.56M
Incyte Corporation develops small molecule drugs to treat serious unmet medical needs. The company has compounds in various stages of development in the areas of oncology, inflammation, diabetes and HIV.
Stock price: $3.53
http://www.incyte.com/

Osteotech, Inc. (NASDAQ:OSTE)
Market Cap: $44.16M
Osteotech, Inc. develops tissue forms and products to create procedure-specific solutions to repair and replace bone loss caused by trauma or disease, augment prosthetic implant procedures, facilitate spinal fusion, and replace and/or repair damaged ligaments and tendons.
Stock price: $2.34
http://www.osteotech.com/

ReNeuron Group Plc (LON:RENE)
Market Cap: $5.87M
ReNeuron Group Plc develops and commercializes stem cell technologies for therapeutic and non-therapeutic applications such as academic and commercial research.
Stock price: $3.65
http://www.reneuron.com

RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN)
Market Cap: $61.35M
RegeneRx Biopharmaceuticals, Inc. develops molecules to promote tissue and organ repair.
Stock price: $1.20
http://www.regenerx.com/

Sangamo BioSciences, Inc. (NASDAQ:SGMO)
Market Cap: $275.38M
Sangamo BioSciences, Inc. develops and commercializes transcription factors for gene regulation and gene modification using a technology platform enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins (ZFPs) that can turn genes on or off and ZFP nucleases (ZFNs), proteins that enable modification of DNA sequences in various ways.
Stock price: $2.59
http://www.sangamo.com/

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
Market Cap: $54.20M
Spectrum Pharmaceuticals, Inc. acquires, develops and commercializes a portfolio of drug products, with a focus on oncology, urology and other critical health challenges.
Stock price: $1.39
http://www.spectrumpharm.com/

StemCells, Inc. (NASDAQ:STEM)
Market Cap: $147.52M
StemCells, Inc. develops cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The company has product development programs for both the human neural stem cell and human liver engrafting cells.
Stock price: $1.17
http://www.stemcellsinc.com/

TiGenix NV (EBR:TIG)
Market Cap: $65.78M
TiGenix NV develops local treatments for damaged and osteoarthritic joints.
Stock price: $2.41
http://www.tigenix.com

Transition Therapeutics Inc. (TSE:TTH)
Market Cap: $93.98M
Transition Therapeutics Inc. develops therapeutics for disease indications with large markets.
Stock price: $2.77
http://www.transitiontherapeutics.com/

Vical Incorporated (NASDAQ:VICL)
Market Cap: $62.54M
Vical Incorporated develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Stock price: $2.77
Stem Cell Stocks Trading Under $1

Angel Biotechnology Holdings Plc (LON:ABH)
Market Cap: $1.64M
Angel Biotechnology Holdings Plc manufactures and supplies biomaterials for use in clinical trials through all phases of the drug development process and for product launch.
Stock price: $0.09
http://www.angelbio.com

Advanced Cell Technology, Inc. (OTC:ACTC)
Market Cap: $3.07M
Advanced Cell Technology, Inc. develops and commercializes human embryonic and adult stem cell technology in the field of regenerative medicine.
Stock price: $0.03
http://www.advancedcell.com

Aeolus Pharmaceuticals, Inc. (OTC:AOLS)
Market Cap: $10.22M
Aeolus Pharmaceuticals, Inc. develops catalytic antioxidant compounds for diseases and disorders of the central nervous system, respiratory system, autoimmune system and oncology. The company’s initial target applications are for the side effects of mustard gas exposure, cancer radiation therapy and amyotrophic lateral sclerosis (ALS).
Stock price: $0.30
http://www.aeoluspharma.com

Aastrom Biosciences, Inc. (NASDAQ:ASTM)
Market Cap: $63.76M
Aastrom Biosciences, Inc. develops autologous cell products for the repair or regeneration of human tissue.
Stock price: $0.48
http://www.aastrom.com/

Athersys, Inc. (NASDAQ:ATHX)
Market Cap: $7.57M
Athersys, Inc. develops therapeutic product candidates as treatments for obesity, damage from myocardial infarction, and conditions affecting the central nervous system.
Stock price: $0.37
http://www.athersys.com

AVI BioPharma, Inc. (NASDAQ:AVII)
Market Cap: $70.48M
AVI BioPharma, Inc. develops therapeutic products principally based on third-generation NeuGene antisense technology. The company targets life-threatening diseases, including cardiovascular, infectious, and genetic diseases.
Stock price: $0.70
http://www.avibio.com/

BrainStorm Cell Therapeutics Inc. (OTC:BCLI)
Market Cap: $4.50M
BrainStorm Cell Therapeutics, Inc. develops stem cell technologies as treatments for currently incurable neurodegenerative diseases. The company primarily focuses on developing NTF cells from a patient’s own bone marrow in order to treat Parkinson, ALS, and spinal cord injury.
Stock price: $0.11
http://www.brainstorm-cell.com/

Cryo-Cell International, Inc. (OTC:CCEL)
Market Cap: $5.89M
Cryo-Cell International, Inc. engages in cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood stem cells for family use.
Stock price: $0.60
http://www.cryo-cell.com/

Cell Genesys, Inc. (NASDAQ:CEGE)
Market Cap: $28.35M
Cell Genesys, Inc. develops and commercializes biological therapies for patients with cancer.
Stock price: $0.25
http://www.cellgenesys.com

Cordlife Ltd. (PINK:CORFF)
Market Cap: $-
CordLife Ltd owns and operates the largest network of private cord blood banks in the Asia Pacific region.
Stock price: $0.16
http://www.cordlife.com/

Curis, Inc. (NASDAQ:CRIS)
Market Cap: $58.39M
Curis, Inc. leverages signaling pathway drug technologies to create new medicines, primarily for cancer.
Stock price: $0.79
http://www.curis.com

Forticell Bioscience, Inc. (OTC:FORB)
Market Cap: $667,901.00
Forticell Bioscience, Inc. is a development stage tissue engineering company with capabilities in cell culturing, biology and biomaterials.
Stock price: $0.02
http://www.forticellbioscience.com

PharmaGap Inc. (CVE:GAP)
Market Cap: $4.09M
PharmaGap Inc. designs and develops therapeutic drugs for the treatment of cancer and other human diseases associated with the human Protein Kinase C enzyme (PKC). PKC is expressed in abnormal levels in many types of cancer and other diseases, such as diabetes.
Stock price: $0.08
http://www.pharmagap.com/

HemaCare Corporation (OTC:HEMA)
Market Cap: $2.95M
HemaCare Corporation collects, processes and distributes blood products to hospitals and research related organizations. It operates and manages donor centers and mobile donor vehicles to collect transfusable blood products. Additionally, HemaCare provides blood related services, principally therapeutic apheresis procedures, stem cell collection and other blood treatments to patients with a variety of disorders.
Stock price: $0.30
http://www.hemacare.com/

International Stem Cell Corporation (OTC:ISCO)
Market Cap: $8.28M
International Stem Cell develops therapeutic and research products with the objective of creating an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal and corneal disease through cell transplant therapy. To assist with this, it has developed pluripotent human stem cells from unfertilized human eggs, and techniques to cause those stem cells to be “differentiated” into the specific cell types required for transplant.
Stock price: $0.19
http://www.internationalstemcell.com/

ThermoGenesis Corp. (NASDAQ:KOOL)
Market Cap: $26.33M
ThermoGenesis Corp. designs, manufactures and markets automated and semi-automated devices and single-use processing disposables that enable hospitals and blood banks to manufacture a therapeutic dose of stem cells, wound healing proteins or growth factors from a single unit of cord blood or the patient’s own blood in less than one hour.
Stock price: $0.39
http://www.thermogenesis.com/

Lifebank Corp. (CVE:LBK)
Market Cap: $1.26M
Lifebank Corp. cryopreserves umbilical cord blood stem cells for families.
Stock price: $0.19
http://www.lifebank.com/

Mesoblast Limited (ASX:MSB)
Market Cap: $118.06M
Mesoblast Limited commercializes adult stem cell technology aimed at the regeneration and repair of bone and cartilage.
Stock price: $0.88
http://www.mesoblast.com

NeoStem, Inc. (AMEX:NBS)
Market Cap: $5.57M
NeoStem, Inc. operates commercial autologous adult stem cell banks.
Stock price: $0.97
http://www.neostem.com/

Orchestra Therapeutics, Inc. (OTC:OCHT)
Market Cap: $421,107.00
Orchestra Therapeutics, Inc., develops products to treat autoimmune and infectious diseases.
Stock price: $0.03
http://www.orchestratherapeutics.com

Opexa Therapeutics, Inc. (NASDAQ:OPXA)
Market Cap: $2.33M
Opexa Therapeutics, Inc. develops autologous cellular therapies to treat several illnesses, including multiple sclerosis, rheumatoid arthritis, and diabetes. These therapies are based on the Company’s T-cell and adult stem cell technologies.
Stock price: $0.16
http://www.opexatherapeutics.com/

Protide Pharmaceuticals, Inc. (OTCPMD)
Market Cap: $245,777.00
Protide Pharmaceuticals, Inc. develops and commercializes technologies and processes in clinical cell therapy, transfusion medicine, cell engineering and transplantation.
Stock price: $0.15
http://www.protidepharma.com

Pluristem Therapeutics Inc. (NASDAQSTI)
Market Cap: $7.08M
Pluristem Therapeutics Inc. commercializes non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. It is developing a pipeline of products derived from human placenta.
Stock price: $0.48
http://www.pluristem.com/

Stem Cell Authority Ltd. (PINK:SCAL)
Market Cap: $6.53M
Stem Cell Authority Ltd focuses on the collection and banking of mesenchymal stem cell technology for autologous stem cell banking.
Stock price: $0.03
http://www.stemcellauthority.com/

Stem Cell Therapeutics (PINK:SCTPF)
Market Cap: $7.47M
Stem Cell Therapeutics Corp. develops and commercializes drug-based therapies to treat central nervous system diseases that stimulate a patient’s own resident stem cells.
Stock price: $0.03
http://www.stemcellthera.com/

Titan Pharmaceuticals, Inc. (AMEX:TTP)
Market Cap: $9.91M
Titan Pharmaceuticals, Inc. develops therapeutics primarily for the treatment of central nervous system disorders.
Stock price: $0.10
http://www.titanpharm.com/

Vitro Diagnostics, Inc. (OTC:VODG)
Market Cap: $1.21M
Vitro Diagnostics, Inc. develops and commercializes products derived from its human cell line research — predominantly related to diabetes. Vitro has created a patent-pending method to generate adult stem cells from tissues. The Company plans to extend their product line to include stem cell-derived human beta islet cells for use in research and drug discovery.
Stock price: $0.04

 

[The Boys]

Shares of Geron soared Friday evening, up more than 36% on word that President Barack Obama will sign an executive order Monday lifting President Bush?s limit on embryonic stem-cell research funding. StemCells Inc. also rose more than 53% on the news. Cytori Therapeutics was up 23%.

 

[djv]

Anyone know of a ETF that includes much of the above list.
Tks

 

[new redneck]

boys, looking forward to monday ! as you might know i am very long in geron.. what is interesting is the rise in stem on the news.. i think it is all about the name, as the executive order is about embryonic stem cells, and stem is not involved in any way with esc,s !! premarket should be interesting.. based on some posts here by dodger blue, i looked at and have been buying actc, another esc play.. do not post here often, but appreciate those of you who do, and love the board .....doc

 

[dawgball]

"Hallelujah! This marks the end of a long and repressive chapter in scientific history. It's the stem-cell 'emancipation proclamation'," said Dr. Robert Lanza of Massachusetts-based Advanced Cell Technology, a stem cell company.

This is from story that was on Google news front page on the reader. It's very encouraging that ACTC.pk is getting some of the press along with the bigger boys.

http://www.reuters.com/article/healthNews/idUSTRE5271SZ20090308

 

[vinnie]

ring the register these small companies will run out of money & big pharma will take over

 

[dawgball]

ring the register these small companies will run out of money & big pharma will take over

I'll check in the morning. I think I have a sell order at 0.25 for almost all of it. I'm not sure it will go that far tomorrow, though.

 

[ImFeklhr]

Such weird and serious issue to make money on.

Not condeming it, just suddenly thought that.

 

[vinnie]

Such weird and serious issue to make money on.

Not condeming it, just suddenly thought that.

where ever there is somewhere to make a buck someone will be there grabbing it :shrug:

 

[MadJack]

I'll check in the morning. I think I have a sell order at 0.25 for almost all of it. I'm not sure it will go that far tomorrow, though.

.195/.20 pre market on 95000 volumn, so you could make it

whatever the high is for the day, I doubt it holds, so I think you have a good plan there.

 

[BleedDodgerBlue]

I think you might hit your number, but agree it probably won't hold. might close around .19 still close to a one day double

for me it's a long term anyway, and hoping for 2 bucks in the next couple years. i'll be able to buy madjacks and put in the much needed filter to eliminate raven and cowboys discussion.

anyway, i think actc is such a manipulated stock anyway. i mean its a pink. how can it have volume after hours pre market. i still love the potential, but the real money comes pps when it gets off the pink and turns over a financial.


gl

 

[vinnie]

I'll check in the morning. I think I have a sell order at 0.25 for almost all of it. I'm not sure it will go that far tomorrow, though.

Nice hope it gets there :mj06:

 

[smurphy]

:nooo:

 

[vinnie]

:nooo:

yep after the all hype of the Obama reversal wears off these stocks will go back to their lows :sadwave: way before if or when they ever go anywhere

 

[dawgball]

yep after the all hype of the Obama reversal wears off these stocks will go back to their lows :sadwave: way before if or when they ever go anywhere

perfect example of "Buy the rumor; sell the news"

 

[DOGS THAT BARK]

ring the register these small companies will run out of money & big pharma will take over

I don't think pharmacuticals want any part of it unless uncle sam is picking up the tab.

Privite enterprise and even states have had green light on this research all along aswell as other countries--only thing GW did was cut federal funding.

Privite parties abandoned reseach for most part in late 90's